Reuters logo
BRIEF-Soligenix receives $1.5 mln to support Phase 3 clinical trial of SGX301​
September 29, 2017 / 9:18 PM / 3 months ago

BRIEF-Soligenix receives $1.5 mln to support Phase 3 clinical trial of SGX301​

Sept 29 (Reuters) - Soligenix Inc

* Soligenix - ‍national Institutes of Health awarded co about $1.5 million over 2 years to support conduct of pivotal Phase 3 clinical trial evaluating SGX301​ Source text: (bit.ly/2yemsz3) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below